Curated News
By: NewsRamp Editorial Staff
September 15, 2025
GeoVax's Multi-Antigen COVID Vaccine Shows Superiority in CLL Patients
TLDR
- GeoVax's GEO-CM04S1 vaccine outperforms mRNA vaccines in CLL patients, positioning the company to capture a multi-billion dollar underserved market with superior immune response.
- GEO-CM04S1 uses a Modified Vaccinia Ankara vector encoding both Spike and Nucleocapsid proteins to drive broad, cross-variant immune protection in immunocompromised patients.
- This vaccine breakthrough provides better protection for immunocompromised cancer patients who remain vulnerable with current vaccines, improving health equity and safety.
- A novel dual-antigen COVID vaccine shows promising results in leukemia patients, using a unique viral vector platform that could revolutionize protection for vulnerable populations.
Impact - Why it Matters
This development is crucial because immunocompromised individuals, such as those with chronic lymphocytic leukemia (CLL), have been disproportionately affected by COVID-19 due to inadequate protection from existing vaccines. GEO-CM04S1's success could fill a critical gap, offering enhanced immunity and reducing severe outcomes in vulnerable populations. It represents a significant advancement in pandemic preparedness, potentially saving lives and reducing healthcare burdens by addressing a multi-billion-dollar market need for durable, cross-variant protection.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has announced promising interim results for its multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, presented at the XXI International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland. The data, shared by Professor Alexey V. Danilov from City of Hope, comes from an ongoing randomized Phase 2 trial (NCT05672355) comparing GEO-CM04S1 to a standard mRNA vaccine in patients with chronic lymphocytic leukemia (CLL). Key findings include GEO-CM04S1 meeting the study's primary immune endpoint statistically, leading to exclusive enrollment in its arm per the Data Safety Monitoring Board's recommendation, while the mRNA comparator did not achieve this benchmark. Both vaccines demonstrated a favorable safety profile with no severe adverse events reported.
GEO-CM04S1 is a next-generation vaccine built on a Modified Vaccinia Ankara (MVA) vector, encoding both the Spike and Nucleocapsid proteins of SARS-CoV-2 to provide broad, durable immune protection. It is currently in three Phase 2 trials: as a primary vaccine for immunocompromised patients, a booster for CLL patients, and a robust booster for mRNA-vaccinated healthy adults. David Dodd, Chairman & CEO of GeoVax, emphasized the vaccine's potential to address unmet needs in high-risk populations where current vaccines fall short, highlighting both clinical and commercial opportunities. For more details, visit www.geovax.com or view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax's Multi-Antigen COVID Vaccine Shows Superiority in CLL Patients
